Salivary Gland Cancer

P2, N=46, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Jul 2022 --> Jul 2028

The diagnosis required pathology and molecular testing. MAML2 rearrangement suggests a better prognosis; further research is needed to elucidate its pathogenesis and improve its treatment.

P=N/A, N=600, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P1, N=45, Recruiting, Baylor College of Medicine | Trial primary completion date: Dec 2025 --> Dec 2026

Clinical implications are direct: SGTs in BRCA1 carriers should not be assumed eligible for PARP inhibitor therapy without HRD confirmation, and enhanced surveillance appears unwarranted. This case underscores that co-occurrence does not establish causation and highlights the critical importance of functional validation before expanding hereditary cancer spectra.

The report highlights a case of pulmonary HCCC with negative PD-L1. The combination of tumor location, immunophenotypes and genetic alterations would be harnessed to differentiate HCCC from other tumors.

P=N/A, N=0, Recruiting, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiaotong University Scho

T-DXd has emerged as a transformative therapy across HER2-driven malignancies, leading to histology-specific and tissue-agnostic approvals. Vigilant ILD monitoring is essential, and further research is warranted to refine biomarkers, address resistance, and explore rational drug combinations. T-DXd exemplifies the paradigm shift of antibody-drug conjugates toward pan-cancer precision oncology.

Although HER2-positive (3 +) was seen only in SDC, HER2-low and HER2-ultra-low expressions were not uncommon across salivary gland carcinomas, including SDCs and various non-SDC types. These findings suggest the potential applicability of HER2-targeted therapy in salivary gland carcinomas.

We report the case of a middle-aged man with HER2-positive metastatic SDC who achieved near-complete pathologic and radiological response to trastuzumab and docetaxel, enabling surgical resection for locoregional control. This case highlights the role of anti-HER2 therapy as a first-line strategy in SDC and underscores the importance of individualized management plans integrating systemic treatment and locoregional measures.

Thus, the potential for AGE10 as a diagnostic marker is limited. The implications concern the biology of this epitope, the unique tissue distribution, and a role in cellular metabolism.